Calculation of pharmacokinetic and dosimetric characteristics of albumin microspheres labeled with Re-188 for various routes of administration

«Radiation and Risk», 2026, vol. 35, No. 1, pp.103-116

DOI: 10.21870/0131-3878-2026-35-1-103-116

Authors

Matveev A.V. – Head of Dep., Associate Prof., C. Sc., Phys.-Math. OmSMU. Contacts: 12 Lenina str., Omsk, Russia, 644099; e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it. .
Tishchenko V.K. – Head of Lab., D. Sc., Biol. A. Tsyb MRRC.
¹ Omsk State Medical University of the Ministry of Health of the Russian Federation, Omsk
² A. Tsyb MRRC, Obninsk

Abstract

Radiopharmaceutical drugs labeled with ¹⁸⁸Re are widely used in bone metastases, hepatocellular carcinoma and metastatic liver damage, skin tumors, for the treatment of keloid lesions, rheumatoid arthritis and synovitis. New therapeutic radiopharmaceutical drugs with ¹⁸⁸Re are also currently being developed. Human serum albumin microspheres (HSA) are unique carriers for the selective and controlled radionuclide delivery to malignant tumors. The aim of the work is to develop a chamber mathematical model of the kinetics of ¹⁸⁸Re labeled HSA (¹⁸⁸Re-HSA) in laboratory animals with various routes of administration and calculate the pharmacokinetic and dosimetric characteristics of this drug based on it. The studies were carried out on outbred white mice and inbred C57BL/6 mice with trans-planted Lewis adenocarcinoma after intravenous, intramuscular and intratumoral administration. The object of the study is ¹⁸⁸Re-HSA with a diameter of 10-20 microns. The kinetic parameters of the model were identified using experimental data on the biodistribution of ¹⁸⁸Re-HSA in mouse organs and tissues. Calculations of the pharmacokinetic and dosimetric characteristics of ¹⁸⁸Re-HSA in laboratory animals were based on the identified kinetic parameters. The simulation results showed that the pharmacokinetic and dosimetric characteristics of ¹⁸⁸Re-HSA in the body significantly depend on the administration route. The highest concentration of ¹⁸⁸Re-HSA in organs and tissues with maximum accumulation in the lungs was observed after intravenous administration. After intramuscular or intratumoral administration the concentration of ¹⁸⁸Re-HSA in organs and tissues was significantly lower, and the maximum concentration remained in the injection chamber for a long time. An increased accumulation of ¹⁸⁸Re-HSA in the thyroid gland was also detected after all routes of administration. The maximum values of absorbed doses were obtained in the lung chamber after intrave-nous administration, in the thigh muscle chamber after intramuscular administration, and in the tumor chamber after intratumoral administration. The obtained results can be used to evaluate the ¹⁸⁸Re-HSA potential for tumor therapy after intravascular or intratumoral administration.

Key words
rhenium-188, radiopharmaceutical, pharmacokinetics, compartmental modeling, nuclear medicine, absorbed dose, human serum albumin, radiobiology.

References

1. Petriev V.M., Shiryaev V.K., Smakhtin L.A., Skvortsov V.G. Development of a procedure for preparing 103Pd-microspheres of human blood albumin, a potential radiopharmaceutical for treatment of malignant tu-mors. Radiochemistry, 2010, vol. 52, no. 2, pp. 207-211.

2. Li R., Li D., Jia G., Li X., Sun G., Zuo C. Diagnostic performance of theranostic radionuclides used in transarterial radioembolization for liver cancer. Front. Oncol., 2021, vol. 10, pp. 551622. DOI: 10.3389/fonc.2020.551622.

3. Reinders M.T.M., Smith M.J.L., van Roekel C., Braat A.J.A. Holmium-166 microsphere radioembolization of hepatic malignancies. Semin. Nucl. Med., 2019, vol. 49, no. 3, pp. 237-243.

4. Häfeli U.O., Casillas S., Dietz D.W., Pauer G.J., Rybicki L.A., Conzone S.D., Day D.E. Hepatic tumor radio-embolization in a rat model using radioactive rhenium (186Re/188Re) glass microspheres. Int. J. Radiat. Oncol. Biol. Phys., 1999, vol. 44, no. 1, pp. 189-199.

5. Lin Y.C., Tsai S.C., Hung G.U., Lee J.C., Huang Y.S., Lin W.Y. Direct injection of 188Re-microspheres in the treatment of hepatocellular carcinoma. Compared with traditional percutaneous ethanol injection: an animal study. Nuklearmedizin, 2005, vol. 44, no. 3, pp. 76-80.

6. Verger E., Drion P., Meffre G., Bernard C., Duwez L., Lepareur N., Couturier O., Hindré F., Hustinx R., Lacoeuille F. 68Ga and 188Re starch-based microparticles as theranostic tool for the hepatocellular carcinoma: radiolabeling and preliminary in vivo rat studies. PLoS One, 2016, vol. 11, no. 10, pp. e0164626. DOI: 10.1371/journal.pone.0164626.

7. Kaprin A.D., Ivanov S.A., Shegay P.V., Kucherov V.V., Petrosyan A.P., Stepanenko V.P., Tischenko V.K., Sigov M.A., Petrov L.O., Stehova A.T. Radioembolization of the liver by 188Re albumin microspheres 20-40 μm (“HEPATOREN”): results of the first phase of the study. Rossijskij zhurnal personalizirovannoj mediciny – Russian Journal for Personalized Medicine, 2023, vol. 3, no. 5, pp. 74-81. (In Russian).

8. Kucherov V.V., Petrosyan A.P., Vlasova O.P., Sigov M.A., Tishchenko V.K., Spichenkova O.N., Stepanenko V.F., Shegay P.V., Ivanov S.A., Kaprin A.D. Clinical study’s results of the safety of the radio-pharmaceutical labeled with 188Re during intraarterial radioembolization. Radiatsiya i risk – Radiation and Risk, 2024, vol. 33, no 3, pp. 18-29. (In Russian).

9. Stepchenkova E.D., Tishchenko V.K., Vlasova O.P., Petriev V.M., Legkodimova N.S., Krylov V.V., Fedorova A.V., Kuzenkova E.A., Ostroukhoff A.A., Shegai P.V. Radioactivity distribution in the blood and urine of patients receiving systemic therapy with a 177Lu radiopharmaceutical and local (intra-articular) therapy with a 188Re radiopharmaceutical. Vedomosti Nauchnogo tsentra ekspertizy sredstv meditsinskogo prime-neniya. Regulyatornyye issledovaniya i ekspertiza lekarstvennykh sredstv – Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. Regulatory Research and Medicine Evaluation, 2022, vol. 12, no. 4, pp. 404-414 (In Russian).

10. Krylov V.V., Lugovaya A.V., Petrosyan K.M., Sigov M.A., Petriev V.M., Spichenkova O.N., Stepanenko V.F., Khvostunov I.K., Shakhova S.G., Starodubtsev A.L., Kurilchik A.A., Bespalov P.D., Vlasova O.P., Tishchenko V.K., Ivanov S.A., Kaprin A.D., Shegay P.V. Radiosynovectomy of knee joints with the domestic radiopharmaceutical drug "Albumin microspheres 5-10 μm, labeled with 188Re". Proceedings of the VII Inter-national Congress of the Association of Rheumato-Orthopedists. Voronezh, 2023, pp. 143-145. (In Russian).

11. Pillai M.R., Dash A., Knapp F.F. Jr. Rhenium-188: availability from the (188)W/(188)Re generator and status of current applications. Curr. Radiopharm, 2012, vol. 5, no. 3, pp. 228-243.

12. Liepe K., Lymouris L., Krylov V.V., Kochetova T.Yu. Nuclear therapy with 188Re based radiopharmaceuti-cals in oncology. Onkologicheskij zhurnal: luchevaja diagnostika, luchevaja terapija – Journal of Oncology: Diagnostic Radiology and Radiotherapy, 2018, vol. 1, no. 4, pp. 34-42. (In Russian).

13. Tishchenko V.K., Petriev V.M., Vlasova O.P., Stepchenkova E.D. Effect of administration route on the bio-distribution of albumin microspheres labelled with 188Re. Radiatsiya i risk – Radiation and Risk, 2021, vol. 30, no. 4, pp. 85-93. (In Russian).

14. Sergienko V.I., Jelliff R., Bondareva I.B. Applied parmacokinetics: fundamentals and clinical applications. Moscow, RAMS Publ., 2003. 208 p. (In Russian).

15. Meerkhan S., Sjogreen Gleisner K., Larsson E., Strand S.E., Jonsson B.A. Testis dosimetry in individual patients by combining a small-scale dosimetry model and pharmacokinetic modeling-application of (111)In-Ibritumomab Tiuxetan. Phys. Med. Biol., 2014, vol. 59, no. 24, pp. 7889-7904.

16. Galanin M.P., Khodzhaeva S.R. Development and testing for methods of solving stiff ordinary differential equations. Matematicheskoe modelirovanie i chislennye metody – Mathematical Modeling and Numerical Methods, 2014, no. 4, pp. 95-119. (In Russian).

17. Lunev A.S., Lunyova K.A., Klementyeva O.E. Pharmacokinetic studies of radiopharmaceuticals. Vedomosti Nauchnogo tsentra ekspertizy sredstv meditsinskogo primeneniya. Regulyatornye issledovaniya i ekspertiza lekarstvennykh sredstv – Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. Regu-latory Research and Medicine Evaluation, 2022, vol. 12, no. 4, pp. 395-403. (In Russian).

18. Matveev A.V. Calculation of the dosimetric characteristics of the radiopharmaceutical “188Re-albumin micro-spheres” in the body of mice based on pharmacokinetic modeling. Nauchnyj vestnik OmGMU – Scientific Bulletin of OmSMU, 2024, vol. 4, no 2, pp. 34-45. (In Russian).

19. Petriev V.M., Afanas’eva E.L., Skvortsov V.G. Osteotropic radiopharmaceuticals based on phosphonic ac-ids for the treatment of bone metastases in humans (review). Pharmaceutical Chemistry Journal, 2008, vol. 42, no. 5, pp. 233-240.

20. Sgouros G., He B., Ray N., Ludwig D.L., Frey E.C. Dosimetric impact of Ac-227 in accelerator-produced Ac-225 for alpha-emitter radiopharmaceutical therapy of patients with hematological malignancies: a pharmacokinetic modeling analysis. EJNMMI Phys., 2021, vol. 8, no. 1, pp. 60-75.

Full-text article (in Russian)